The relevant listed companies of bnct include Yantai Dongcheng Pharmaceutical Group Co., Ltd., stock code 002675, stock abbreviation Dongcheng Pharmaceutical. On August 28, Dongcheng Pharmaceutical responded to investor questions on an interactive platform and stated that my country's first BNCT device designed and built by the company's joint-stock company China Boron Alliance will be stationed in Xiamen Hongai Hospital.
Yantai Dongcheng Pharmaceutical Group Co., Ltd. was registered and established at the Yantai Administration for Industry and Commerce on December 31, 1998. The legal representative is Shou Yi. The company's business scope includes APIs (heparin sodium, heparin calcium, chondroitin sulfate sodium, chondroitin sulfate sodium (for injection), nadroparin calcium, enoxaparin sodium, dalteparin sodium), etc. .
Boron neutron capture therapy (BNCT) is a newly emerging precision cancer radiotherapy technology. Its treatment principle is to use targeted biological probes to bring the stable isotope boron-10 into cancer cells. The adaptive neutron beam is irradiated locally from outside the body and efficiently triggers micron-level heavy ion radiation therapy in target cells at a fixed point. It is a next-generation tumor radiotherapy technology that combines molecular targeting and heavy ion irradiation. It is expected to elevate tumor treatment to a high level of safety. A new level of safety, high effectiveness and personalized precision treatment. BNCT technology has adopted the latest particle accelerator as the core neutron source system abroad, and many international companies have developed and manufactured BNCT treatment systems and BNCT-specific targeted drugs. As of the end of 2017, BNCT has been built and is in progress worldwide. More than 15 accelerator BNCT treatment centers have been installed, constructed and planned, and some have been approved to enter the clinical verification stage.
In 2020, Academician Chen Hesheng of the Institute of High Energy Physics of the Chinese Academy of Sciences led a team to develop my country's first accelerator BNCT experimental device, laying a solid foundation for the realization of BNCT treatment in China. The targeting and preparation process of boron drugs are crucial. Since 2009, the scientific research team of Gaojin Biotechnology has been conducting intensive research under the leadership of Du Jun, an authoritative expert in domestic tumor targeting and pharmacy circles and a professor at Sun Yat-sen University, and has developed anti-cancer boron drugs. We continue to tackle key problems in the pharmaceutical field and have currently obtained 2 national invention patent authorizations, and 12 more national invention patents are in the process of application. Gaojin Biotech has in-depth and close cooperation with the team of Academician Chen Hesheng, which also ensures that the development of boron drugs and devices are synchronized